ES2522317T3 - Ticagrelor para tratamiento de aneurismas aórticos abdominales - Google Patents
Ticagrelor para tratamiento de aneurismas aórticos abdominales Download PDFInfo
- Publication number
- ES2522317T3 ES2522317T3 ES08857354.8T ES08857354T ES2522317T3 ES 2522317 T3 ES2522317 T3 ES 2522317T3 ES 08857354 T ES08857354 T ES 08857354T ES 2522317 T3 ES2522317 T3 ES 2522317T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- ticagrelor
- aortic aneurysms
- abdominal aortic
- aneurysms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002223 abdominal aortic aneurysm Diseases 0.000 title 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 title 1
- 229960002528 ticagrelor Drugs 0.000 title 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301616 | 2007-12-03 | ||
| EP07301616 | 2007-12-03 | ||
| PCT/SE2008/051386 WO2009072967A1 (en) | 2007-12-03 | 2008-12-02 | Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2522317T3 true ES2522317T3 (es) | 2014-11-14 |
Family
ID=40717966
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08857354.8T Active ES2522317T3 (es) | 2007-12-03 | 2008-12-02 | Ticagrelor para tratamiento de aneurismas aórticos abdominales |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20100298350A1 (enExample) |
| EP (1) | EP2229172B1 (enExample) |
| JP (1) | JP5701060B2 (enExample) |
| KR (1) | KR101563757B1 (enExample) |
| CN (2) | CN101883565A (enExample) |
| AU (1) | AU2008331984B2 (enExample) |
| BR (1) | BRPI0819458A2 (enExample) |
| CA (1) | CA2707488C (enExample) |
| CY (1) | CY1115760T1 (enExample) |
| DK (1) | DK2229172T3 (enExample) |
| EA (1) | EA201000928A1 (enExample) |
| ES (1) | ES2522317T3 (enExample) |
| HR (1) | HRP20141081T1 (enExample) |
| IL (1) | IL205613A (enExample) |
| MX (1) | MX2010006101A (enExample) |
| MY (1) | MY159656A (enExample) |
| NZ (1) | NZ585513A (enExample) |
| PL (1) | PL2229172T3 (enExample) |
| PT (1) | PT2229172E (enExample) |
| RS (1) | RS53635B1 (enExample) |
| SI (1) | SI2229172T1 (enExample) |
| UA (1) | UA100864C2 (enExample) |
| WO (1) | WO2009072967A1 (enExample) |
| ZA (1) | ZA201003599B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102653539B (zh) * | 2011-03-01 | 2014-09-17 | 秦引林 | 一种抗血小板聚集化合物及其药物组合 |
| CN102924457A (zh) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | 三唑并嘧啶类衍生物、其制备方法及其用途 |
| EP2750676B1 (en) | 2011-08-30 | 2018-01-10 | University of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997003084A1 (en) * | 1995-07-11 | 1997-01-30 | Astra Pharmaceuticals Ltd. | New inhibitors of platelet aggregation |
| AR017014A1 (es) * | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| TWI229674B (en) * | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
| WO2009007675A2 (en) * | 2007-07-11 | 2009-01-15 | Cardoz Ab | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist |
-
2008
- 2008-02-12 UA UAA201005772A patent/UA100864C2/uk unknown
- 2008-12-02 RS RS20140600A patent/RS53635B1/sr unknown
- 2008-12-02 PT PT88573548T patent/PT2229172E/pt unknown
- 2008-12-02 SI SI200831311T patent/SI2229172T1/sl unknown
- 2008-12-02 HR HRP20141081AT patent/HRP20141081T1/hr unknown
- 2008-12-02 JP JP2010536888A patent/JP5701060B2/ja active Active
- 2008-12-02 CN CN2008801189070A patent/CN101883565A/zh active Pending
- 2008-12-02 CN CN201410139401.5A patent/CN103919781A/zh active Pending
- 2008-12-02 DK DK08857354.8T patent/DK2229172T3/da active
- 2008-12-02 BR BRPI0819458 patent/BRPI0819458A2/pt not_active Application Discontinuation
- 2008-12-02 MY MYPI2010002526A patent/MY159656A/en unknown
- 2008-12-02 EP EP08857354.8A patent/EP2229172B1/en active Active
- 2008-12-02 MX MX2010006101A patent/MX2010006101A/es active IP Right Grant
- 2008-12-02 ES ES08857354.8T patent/ES2522317T3/es active Active
- 2008-12-02 PL PL08857354T patent/PL2229172T3/pl unknown
- 2008-12-02 AU AU2008331984A patent/AU2008331984B2/en active Active
- 2008-12-02 EA EA201000928A patent/EA201000928A1/ru unknown
- 2008-12-02 US US12/745,733 patent/US20100298350A1/en not_active Abandoned
- 2008-12-02 NZ NZ585513A patent/NZ585513A/en unknown
- 2008-12-02 WO PCT/SE2008/051386 patent/WO2009072967A1/en not_active Ceased
- 2008-12-02 CA CA2707488A patent/CA2707488C/en not_active Expired - Fee Related
- 2008-12-02 KR KR1020107013193A patent/KR101563757B1/ko active Active
-
2010
- 2010-05-06 IL IL205613A patent/IL205613A/en active IP Right Grant
- 2010-05-20 ZA ZA2010/03599A patent/ZA201003599B/en unknown
-
2014
- 2014-10-30 CY CY20141100893T patent/CY1115760T1/el unknown
-
2015
- 2015-01-15 US US14/597,255 patent/US20150272955A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL205613A0 (en) | 2010-11-30 |
| PT2229172E (pt) | 2014-11-03 |
| SI2229172T1 (sl) | 2014-12-31 |
| WO2009072967A1 (en) | 2009-06-11 |
| EP2229172B1 (en) | 2014-09-10 |
| UA100864C2 (uk) | 2013-02-11 |
| HK1148195A1 (en) | 2011-09-02 |
| KR101563757B1 (ko) | 2015-10-27 |
| CA2707488A1 (en) | 2009-06-11 |
| ZA201003599B (en) | 2012-10-31 |
| NZ585513A (en) | 2012-07-27 |
| AU2008331984A1 (en) | 2009-06-11 |
| CN101883565A (zh) | 2010-11-10 |
| MX2010006101A (es) | 2010-10-04 |
| BRPI0819458A2 (pt) | 2015-05-05 |
| KR20100099175A (ko) | 2010-09-10 |
| HRP20141081T1 (hr) | 2015-01-02 |
| JP5701060B2 (ja) | 2015-04-15 |
| CY1115760T1 (el) | 2017-01-25 |
| PL2229172T3 (pl) | 2015-01-30 |
| DK2229172T3 (da) | 2014-11-10 |
| US20150272955A1 (en) | 2015-10-01 |
| EP2229172A4 (en) | 2012-12-26 |
| AU2008331984B2 (en) | 2012-08-16 |
| CA2707488C (en) | 2015-07-28 |
| EP2229172A1 (en) | 2010-09-22 |
| CN103919781A (zh) | 2014-07-16 |
| MY159656A (en) | 2017-01-13 |
| RS53635B1 (sr) | 2015-04-30 |
| IL205613A (en) | 2015-04-30 |
| EA201000928A1 (ru) | 2010-12-30 |
| JP2011505417A (ja) | 2011-02-24 |
| US20100298350A1 (en) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2011002955A1 (es) | Compuestos derivados de 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octanonitrilo o heptanonitrilo o sus sales, como inhibidores de jak; procedimiento de preparacion; composicion farmaceutica que los comprende; utiles para el tratamiento de trastornos autoinmunes, cancer, entre otras enfermedades. | |
| AR059390A1 (es) | Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos | |
| MY147966A (en) | Compositions, suitable for oral administration, comprising a triazolo [4,5-d] pyrimidin derivate | |
| CL2008003023A1 (es) | (s)-4-amino-n-(1-(4-clorofenil)-3-hidroxipropil)-1-(7h-pirrolo[2,3-d]pirimidin-4-il)piperidina-4-carboxamida, inhibidor de la proteina quinasa b; procedimiento de preparacion; compuestos intermediarios; composicion farmacéutica que comprende dicho compuesto; y uso para el tratamiento del cancer. | |
| AR054426A1 (es) | Uso de un inhibidor de la dimerizacion de receptores tirosina quinasas her para la manufactura de un medicamento para alargar el tiempo hasta l a progresion de la enfermedad o la supervivencia de los pacientes de cancer | |
| ES2562651T3 (es) | Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos | |
| UY30094A1 (es) | Compuestos químicos | |
| UY29562A1 (es) | Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| MX373318B (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cáncer. | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| CL2012003503A1 (es) | Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos. | |
| ES2555778T3 (es) | Mejora de la biodisponibilidad de principios activos con función amidina en medicamentos | |
| ECSP088828A (es) | 4-anilinoquinolina-3-carboxamidas como inhibidores de la quinasa csf-1r | |
| NI201400052A (es) | Composiciones farmacéuticas de 7 - ( 6 - ( 2 - hidroxipropano - 2 - il ) piridina - 3 - il ) - 1 - ((trans) - 4 - metoxiciclohexil ) - 3, 4 - dihidropirazino [ 2, 3 - b ] pirazina - 2 ( 1h ) - ona, una forma sólida de las mismas y métodos de su uso | |
| ECSP10010695A (es) | Compuestos de piridina | |
| ECSP099044A (es) | Compuestos de pirimido fusionados | |
| AR083528A1 (es) | Analogos de peptido insulinotropico dependiente de glucosa | |
| CL2008003200A1 (es) | Compuestos derivados de tiazol, inhibidores de la proteina quinasas; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de vejiga, de mama y de rinon. | |
| MX2021015056A (es) | Compuesto de pirrolopirimidina y uso del mismo. | |
| CL2014001309A1 (es) | Compuestos derivados de [1,2,3] triazolo [4,5-d]-pirimidina, agonistas del receptor de canabinoides 2; proceso de obtencion; composicion farmaceutica; uso para el tratamiento o la profilaxis del dolor, aterosclerosis,retinopatia diabetica, diabetes, fibrosis hepatica, fallo cardiaco, entre otras. | |
| ECSP14013130A (es) | N-(6-((2r,3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina | |
| CL2008003396A1 (es) | (3ar,4s,6r,6as)-6-amino-2,2-dimetiltetrahidro-3ah-ciclopena[d][1,3]dioxol-4-ol dibenzoil-l-tartrato y su proceso de preparación. | |
| CR11591A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
| GT200600366A (es) | Compuestos de imidazol sustituido como inhibidores de ksp | |
| UY30880A1 (es) | 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones |